CTLA-4, present on the surface of cluster differentiation (CD) 4+ and CD8+ lymphocytes, is another important pharmacological target for the treatment of several neoplastic forms, including metastatic melanoma [49]. The gene discussed is CD8A; the disease is metastatic melanoma.